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Abstract: Purpose: To investigate changes in the trend of anti-glaucoma ophthalmic solutions in 2000-2008 in a Japanese 
local community. 
Materials and Methods: The subjects of this study were patients with glaucoma who were registered in the database of the 
glaucoma clinic of University of Yamanashi Hospital or the database of the Association for Research in Supporting 
System of Chronic Diseases (ARSSCD). The trend of newly prescribed anti-glaucoma ophthalmic solutions from January 
2000 through July 2008 was analyzed. Changes in the trend of anti-glaucoma ophthalmic solutions and the persistence of 
each anti-glaucoma ophthalmic solution were investigated. 
Results: A total of 1,955 glaucoma patients were enrolled. Mean intraocular pressure (IOP) significantly reduced by year 
(R
2=0.7938, p<0.001). The number of new prescriptions for analysis in the study period was 7,831. Prostaglandin (PG) 
analogues accounted for approximately 40% of the prescriptions during the period, and were followed by beta-blockers 
and carbonic anhydrase inhibitors (CAIs). Those three anti-glaucoma ophthalmic solutions accounted for approximately 
90% of all the prescriptions. Latanoprost showed the longest persistence among the anti-glaucoma ophthalmic solutions. 
The number of newly prescribed anti-glaucoma ophthalmic solutions gradually increased with time. 
Conclusions: PG analogues are the most frequently prescribed and latanoprost showed the longest persistence among the 
anti-glaucoma ophthalmic solutions. PG analogues, beta-blockers, and CAIs accounted for the majority of newly 
prescribed anti-glaucoma ophthalmic solutions. An increase in the number of newly prescribed anti-glaucoma ophthalmic 
solutions may contribute to further IOP reduction. 
Keywords: Glaucoma, anti-glaucoma ophthalmic solutions, prostaglandin, beta-blocker, carbonic anhydrase inhibitor, 
Japanese. 
INTRODUCTION 
  Intraocular pressure (IOP) reduction is the best 
therapeutic choice for glaucoma and sufficient IOP reduction 
is required to maintain visual function. There are two options 
for glaucoma treatment from the aspect to IOP reduction: 
medication and surgery. Surgery dramatically reduces IOP; 
however, it sometimes results in severe complications, such 
as cataract formation, hypotonic maculopathy, and bleb-
related infection [1, 2]. Therefore, the use of anti-glaucoma 
ophthalmic solutions is recommended in many glaucoma 
cases [3]. Recently, new anti-glaucoma ophthalmic solutions 
that can effectively reduce IOP were launched and other 
ophthalmic solutions are expected to be launched in the near 
future. 
  Glaucoma is a vision-threatening disease that requires 
lifelong care. In this regard, ophthalmologists need to devise 
a plan to treat patients in the long term. The treatment plan 
must be personalized for each patient. From this point of 
view, the Association for Research in Supporting System of  
 
 
*Address correspondence to this author at the Department of Community and 
Family Medicine and Department of Ophthalmology, Interdisciplinary 
School of Medicine and Engineering, University of Yamanashi, 1110 
Shimokato Chuo, Yamanashi 409-3898, Japan; Tel: 81-552-73-9657; Fax: 
81-552-73-6757; E-mail: kenjik@yamanashi.ac.jp 
Chronic Diseases (ARSSCD) was established in 2005. A 
new support system for patients with chronic diseases 
including glaucoma was set up in which limited data on 
proper care are shared among participating medical facilities 
through the Internet [4]. This system is considered to be an 
example of the electric health record systems. Important data 
for glaucoma management, such as IOP, medication, and 
visual field test, of registered patients measured at different 
registered medical facilities are collected into the database 
through the Internet. More than 1,400 patients are registered 
with this system so far. Two databases were employed in this 
study: one consists of the medical charts of University of 
Yamanashi Hospital and the other is this Web-based system. 
  It is important to know the trend of anti-glaucoma 
ophthalmic solutions and apply the trend to routine glaucoma 
treatment to keep in touch with current medication status. 
However, as there are few studies in Japan that investigated 
changes in the trend of anti-glaucoma ophthalmic solutions, 
this study attempted to investigate such changes using data 
from the above two systems. 
SUBJECTS AND METHODS 
  This study was conducted in accordance with the 
Helsinki Declaration after receipt of approval from the 
Ethics Committee of Yamanashi University. Consent for the 8    The Open Ophthalmology Journal, 2010, Volume 4  Kenji Kashiwagi 
use of treatment data was obtained from the subjects prior to 
the study. 
  Patients registered with ARSSCD and glaucoma patients 
followed up by the glaucoma clinic of University of 
Yamanashi Hospital were enrolled in this study. Data of IOP 
reduction and newly prescribed anti-glaucoma ophthalmic 
solutions from January 2000 through July 2008 were 
investigated. Goldmann applanation tonometry was 
employed for IOP measurement. Ophthalmic solutions that 
were prescribed only once or for a period of less than one 
month were eliminated from the study. Investigated 
parameters were changes in the trend of anti-glaucoma 
ophthalmic solutions sorted by pharmacological action, 
changes in the trend of anti-glaucoma ophthalmic solutions 
having the same pharmacological action, persistence, and 
changes in the number of newly prescribed anti-glaucoma 
ophthalmic solutions. The above parameters were also 
investigated in patients with normal tension glaucoma 
(NTG). The IOPs of NTG patients never exceeded 21 mmHg 
in any measurements, and the patients did not have a history 
of extensive blood loss or head trauma causing visual field 
loss and disc cupping. They were confirmed not to have any 
intra-cranial abnormalities that would contribute to isual 
field defect and optic nerve atrophy. 
Statistical Analysis 
  Results are expressed as means ± standard deviation. 
JMP (version 5, SAS Institute Inc., NC) was used for 
statistical analysis. 
RESULTS 
Enrolled Subjects 
  A total of 1,955 patients with glaucoma were enrolled in 
this study. Nine hundred and fifty were male and 1,005 were 
female, and the mean age was 66.0±16.5 yrs. The number of 
newly prescribed ophthalmic solutions for analysis in the 
study period was 7,831. The distributions of glaucoma 
subtypes were similar during the study period. Primary open 
angle glaucoma accounted for approximately half of the total 
glaucoma types throughout the study period. NTG was the 
second most popular subtype, its frequency being 
approximately one-quarter of the total glaucoma types. 
Secondary glaucoma and other subtypes accounted for 
approximately another one-quarter of the total glaucoma 
types. 
Changes in Mean IOP 
  During the study period, a total of 52,176 IOP 
measurements were performed. Mean IOP showed a 
significant reduction by year (p<0.0001, Tukey-Kramer test). 
Mean IOP in 2000 was 16.7±4.1mmHg, while that in 2008 
was 15.1±3.7mmHg. There was a significant correlation 
between mean IOP and year (R
2= 0.7938, p<0.001) (Fig. 1). 
Changes in Trend of Anti-Glaucoma Ophthalmic 
Solutions Sorted by Pharmacological Action 
 Among the anti-glaucoma ophthalmic solutions, 
prostaglandin (PG) analogues were the most frequently 
prescribed, accounting for 40% to 45% during the study 
period. Beta-blockers were the second most frequently   
 
prescribed and carbonate anhydrase inhibitors (CAIs) 
followed in the early part of the study period. During follow-
up, the prescription frequency of beta-blockers decreased 
and that of CAIs increased. PG analogues, beta-blockers, and 
CAIs accounted for approximately 90% of all anti-glaucoma 
ophthalmic solutions prescribed during the period (Fig. 2). 
 
Fig. (1). Changes in intraocular pressure by year. Pearson’s 
correlation coefficient was calculated. IOP: intraocular pressure. 
 
Fig. (2). Changes in trend of anti-glaucoma ophthalmic solutions 
sorted by pharmacological action. CAI: carbonic anhydrase 
inhibitor, PG: prostaglandin. 
Changes in Trend of Anti-Glaucoma Ophthalmic 
Solutions having the Same Pharmacological Action 
  Among the PG analogues, latanoprost accounted for 
approximately 90% from 2000 to 2006, but its prescription 
frequency was reduced to 72.5% in 2008 one year after the 
launch of the new PG analogue, travaprost (Fig. 3a). 
  Among the beta-blockers, timolol accounted for 
approximately 60% to 70% during the study period, 
followed by carteolol. The prescription frequency of other 
beta-blockers did not show significant changes during the 
period (Fig. 3b). 
Persistence of Anti-Glaucoma Ophthalmic Solutions 
  Ophthalmic solutions prescribed in 2001 were 
investigated for persistence. PG analogues showed the 
longest persistence among all types of anti-glaucoma 
ophthalmic solutions. PG analogues were prescribed for a 
significantly longer period of 5.3±2.4 yrs than beta-blockers 
(5.0±2.7 yrs) and CAIs (3.8±3.1 yrs). Latanoprost showed 
the longest persistence of 5.8±2.2 yrs among all types of 
anti-glaucoma ophthalmic solutions (Fig. 4). 
R
2 = 0.7938
16 5
17
(mmHg)
15.5
16
16.5
I
O
P
P<0.001
14
14.5
15
2000 2001 2002 2003 2004 2005 2006 2007 2008 2000 2001 2002 2003 2004 2005 2006 2007 2008
year
90%
100%
70%
80%
90%
Bunazosin
50%
60%
Bunazosin
Epinephrine
Pilocarpine
CAI
30%
40%
CAI
Beta-blocker
PG
0%
10%
20%
0%
2000 2001 2002 2003 2004 2005 2006 2007 2008
yearChanges in Trend of Anti-Glaucoma Prescriptions  The Open Ophthalmology Journal, 2010, Volume 4    9 
 
Fig. (3). Changes in trend of anti-glaucoma ophthalmic solutions 
having the same pharmacological action. 
 
Fig. (4). Persistence of anti-glaucoma ophthalmic solutions. p< 
0.05, one-way repeated measures ANOVA and post hoc analysis 
with the Tukey-Kramer test. CAI: carbonic anhydrase inhibitor, 
PG: prostaglandin, SD: standard deviation. 
Changes in the Number of Newly Prescribed Anti-
Glaucoma Ophthalmic Solutions 
  The number of newly prescribed anti-glaucoma 
ophthalmic solutions per glaucoma patient ranged from 1.5 
to 1.8 during the study period and the frequency slightly 
increased with time (Fig. 5). 
Changes in Trend and Persistence of Anti-Glaucoma 
Ophthalmic Solutions among NTG Patients 
  The number of NTG patients was 249 (113 males and 
136 females) and the number of newly prescribed 
ophthalmic solutions was 453. Fig. (6) shows the averaged 
frequency of anti-glaucoma ophthalmic solutions during the 
study period. PG analogues accounted for approximately 
50%, followed by beta-blockers and CAIs. Those three anti-
glaucoma ophthalmic solutions accounted for 95% of all new 
prescriptions. Then, ophthalmic solutions prescribed from 
2001 to 2004 were investigated for their persistence (Fig. 7). 
Latanoprost showed a significantly longer prescription 
period of 4.6±1.0 yrs than beta-blockers (3.9±1.7 yrs) and 
CAIs (3.4±1.4 yrs). 
 
Fig. (5). Changes in the number of newly prescribed anti-glaucoma 
ophthalmic solutions. Pearson’s correlation coefficient was 
calculated. 
 
Fig. (6). Average prescription frequency of anti-glaucoma 
ophthalmic solutions in NTG patients. NTG: normal tension 
glaucoma, PG: prostaglandin, CAI: carbonic anhydrase inhibitor 
DISCUSSION 
  IOP reduction is the most effective therapy for glaucoma. 
Several new anti-glaucoma ophthalmic solutions were 
launched in recent years. The Japan Glaucoma Society 
recommends topical treatment as the first-line treatment for 
glaucoma [3]. Changes in the trend of IOP control and anti-
glaucoma ophthalmic solutions from 2000 through 2008 
were investigated. It is important to investigate the trend of 
IOP control and anti-glaucoma ophthalmic solutions with a 
large population because glaucoma often requires lifelong 
treatment. 
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Fig. (7). Persistence of anti-glaucoma ophthalmic solutions among 
NTG patients. * p< 0.05, p< 0.05, one-way repeated measures 
ANOVA and post hoc analysis with the Tukey-Kramer test. NTG: 
normal tension glaucoma, CAI: carbonic anhydrase inhibitor. 
  The increased reduction of mean IOP by year is an 
indication that ophthalmologists now recognize the fact that 
much greater IOP reduction than ever is required to maintain 
visual function in glaucoma patients. This result also 
indicates that improvements in medical therapy enable 
further IOP reduction. 
  Although the Japan Glaucoma Society recommended 
beta-blockers and PG analogues as the first-line treatment for 
glaucoma [3], this study revealed that PG analogues, in 
particular latanoprost, were the most frequently used anti-
glaucoma ophthalmic solutions. Anti-glaucoma ophthalmic 
solutions are required to possess the following 
characteristics: excellent potential for IOP reduction, good 
tolerance, and little adverse effects. PG analogues, in 
particular latanoprost, are considered to be a good candidate 
[5-7]. 
  Beta-blockers occupied second place during the early 
part of the study period, but CAIs moved up to second place 
in the later part of the study period. CAIs significantly 
reduce IOP in 24 hours, while beta-blockers have low 
potential to reduce IOP at night [8-12]. It is recommended 
that IOP be kept at a sufficiently low level for 24 hours to 
prevent progression of glaucomatous optic neuropathy [3]. 
The trend of anti-glaucoma ophthalmic solutions was similar 
between all types of glaucoma and NTG. PG analogues, 
beta-blockers, and CAIs accounted for 90% of all the 
prescribed anti-glaucoma ophthalmic solutions. 
  Among the beta-blockers, timolol was the most 
frequently prescribed during the study period. It has been 
reported that there is no significant difference in IOP 
reduction among the beta-blockers [13-15]. Timolol has the 
longest history as an anti-glaucoma ophthalmic solution and 
sufficient data of its adverse effects are available. Several 
modifications of timolol, including the once-a-day type and 
the generic type, were launched in recent years. These may 
explain why timolol is the most frequently prescribed among 
the beta-blockers. 
  In Japan, only two PG analogues were available before 
2007: isopropyl unoprostone and latanoprost. Latanoprost 
shows superior IOP reduction compared with isopropyl 
unoprostone [16-18]. However, the launch of travoprost   
 
reduced the frequency of latanoprost prescription. In the near 
future, other PG analogues, such as bimatoprost and 
tafluprost, will be released in Japan. Although it is not clear 
which PG analogue shows superior IOP reduction or the 
least adverse effects [19-21]. PG analogues on the whole are 
expected to be the most frequently prescribed anti-glaucoma 
ophthalmic solutions. However, the frequency of latanoprost 
prescription is expected to be reduced. 
  As anti-glaucoma ophthalmic solutions are usually used 
for a very long time or even a lifetime, it is desirable that 
they have high persistence and adherence [22]. It has been 
reported that latanoprost has high persistence and adherence 
compared to other ophthalmic solutions [23]. The current 
study revealed that latanoprost has the highest persistence 
among all types of anti-glaucoma ophthalmic solutions. The 
persistence of latanoprost is excellent for all types of 
glaucoma. Latanoprost, unoprostone, and beta-blockers were 
the first-line anti-glaucoma ophthalmic solutions in 2001. 
Therefore, latanoprost may have the highest persistence 
among the first-line anti-glaucoma ophthalmic solutions. 
CAIs and other drugs are used as second-line or third-line 
drugs except in very limited cases and the first-line drug 
usually shows the highest persistence regardless of 
adherence. The number of potential first-line anti-glaucoma 
ophthalmic solutions is increasing. Therefore, the real 
persistence of ophthalmic solutions should be determined 
using another method. 
  The current study revealed that the number of anti-
glaucoma ophthalmic solutions gradually increased during 
the follow-up period. Modern glaucoma therapy requires 
much greater IOP reduction that ever. It has been reported 
that 30% IOP reduction from the baseline was preferred in 
patients with NTG [24]. However, it is not easy to reduce 
IOP by 30% with only one anti-glaucoma ophthalmic 
solution, particularly in the case of NTG. This could be one 
reason why the number of anti-glaucoma ophthalmic 
solutions gradually increased during the follow-up period. 
Another reason is that any combinations of anti-glaucoma 
solutions are not authorized by the Japanese government. 
  The subjects of the study are mainly residents of 
Yamanashi Prefecture and neighboring areas. Therefore, the 
current results may not represent the national trend of anti-
glaucoma ophthalmic solutions. It is necessary to conduct a 
similar study using a much larger number of patients from a 
wider area. Furthermore, it is necessary to investigate the 
effects of changes in the trend of anti-glaucoma ophthalmic 
solutions on the extent of IOP reduction or visual function. 
  The current study demonstrated that the development of 
new anti-glaucoma ophthalmic solutions has contributed to 
the reduction of IOP to a much greater extent than ever. New 
anti-glaucoma ophthalmic solutions scheduled for release in 
the near future are expected to contribute to the maintenance 
of visual function in glaucoma patients. However, the 
emergence of new treatment may lead to some negative 
issues, such as the increased possibility of adverse effects 
and the economic burden to not only the patient but also the 
society. Clearly, there is a need to pursue the appropriate 
medication for glaucoma patients while paying attention to 
the above-described issues. 
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